NPM1 and acute myeloid leukemia: About the additional mutations that can be detected in AML, the ELN consensus states that some mutational assays, such as those for NPM1, CEBPA, RUNX1, FLT3, ASXL1, and TP53, could be useful for predicting the outcome and helping to perform ab initio a patient-oriented therapy [1].